Last reviewed · How we verify
r-FSH plus HP-hMG
A combination of recombinant follicle-stimulating hormone (r-FSH) and highly purified human menopausal gonadotropin (HP-hMG) that stimulates ovarian follicle development and hormone production for assisted reproductive technology.
A combination of recombinant follicle-stimulating hormone (r-FSH) and highly purified human menopausal gonadotropin (HP-hMG) that stimulates ovarian follicle development and hormone production for assisted reproductive technology. Used for Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF).
At a glance
| Generic name | r-FSH plus HP-hMG |
|---|---|
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | Gonadotropin combination |
| Target | FSH receptor, LH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
r-FSH directly stimulates follicle-stimulating hormone receptors on granulosa cells to promote follicle growth and estrogen production. HP-hMG provides additional luteinizing hormone (LH) activity to support androgen production in theca cells and final oocyte maturation. Together, they coordinate the hormonal cascade necessary for controlled ovarian hyperstimulation in fertility treatment.
Approved indications
- Ovarian stimulation for assisted reproductive technology (ART) including in vitro fertilization (IVF)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal pain/bloating
- Nausea
Key clinical trials
- Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP (NA)
- Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
- Impact of Three Different Gonadotrophin Regimes on Egg Donation Program (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-FSH plus HP-hMG CI brief — competitive landscape report
- r-FSH plus HP-hMG updates RSS · CI watch RSS
- Instituto Valenciano de Infertilidad, IVI VALENCIA portfolio CI